Literature DB >> 22651114

Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.

Qingshu Lu1, Siu-Keung Tse, Shein-Chung Chow, Min Lin.   

Abstract

In the pharmaceutical industry, a two-stage seamless adaptive design that combines two separate independent clinical trials into a single clinical study is commonly employed in clinical research and development. In practice, in the interest of shortening the development process, it is not uncommon to consider study endpoints with different treatment durations at different stages (Chow and Chang, 2006 ; Maca et al., 2006 ). In this study, our attention is placed on the case where the study endpoints of interest are time-to-event data where the durations at the two stages are different with nonuniform patient entry and losses to follow-up or dropouts. Test statistics for the final analysis based on the combined data are developed under various hypotheses for testing equality, superiority, noninferiority, and equivalence. In addition, formulas for sample size calculation and allocation between the two stages based on the proposed test statistic are derived.

Entities:  

Mesh:

Year:  2012        PMID: 22651114     DOI: 10.1080/10543406.2012.678528

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  J Biopharm Stat       Date:  2014-10-16       Impact factor: 1.051

2.  Power and sample size for randomized phase III survival trials under the Weibull model.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

Review 3.  Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic.

Authors:  Claudia Filozof; Shein-Chung Chow; Lara Dimick-Santos; Yeh-Fong Chen; Richard N Williams; Barry J Goldstein; Arun Sanyal
Journal:  Hepatol Commun       Date:  2017-08-01

4.  Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects.

Authors:  Adam C Palmer; Peter K Sorger; Deborah Plana; Geoffrey Fell; Brian M Alexander
Journal:  Nat Commun       Date:  2022-02-15       Impact factor: 17.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.